Ixekizumab (Taltz): A Patient’s Guide
Ixekizumab is a prescription biologic medicine that blocks an immune protein called IL-17A. It is used to treat plaque psoriasis and certain forms of psoriatic arthritis or spondyloarthritis, including ankylosing spondylitis and non-radiographic axial spondyloarthritis.
Ixekizumab can help reduce symptoms of inflammatory skin and joint conditions, usually with regular injections. Your doctor or pharmacist should confirm whether it is appropriate for you and teach you how to use it safely.
Key facts at a glance
- ATC
- L04AC13
- RxNorm
- 1745099
- Generic
- Ixekizumab
- Class
- atc-l04
- Brands
- Taltz
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- prefilled syringe
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Dosage and administration
- Usual dose
- 160 mg initial dose, then 80 mg
- Maximum
- consult physician
- Frequency
- every 2 weeks for 12 weeks, then every 4 weeks
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 160 mg initial dose, then 80 mg
- Maximum
- consult physician
- Frequency
- every 2 weeks for 12 weeks, then every 4 weeks
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 160 mg initial dose, then 80 mg
- Maximum
- consult physician
- Frequency
- every 2 weeks for 12 weeks, then every 4 weeks
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
Overdose information
Special Populations
11 groupspregnancy
first trimesteravoid if possible
Ixekizumab should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus
regular prenatal care and fetal monitoring
Use with caution and monitor for adverse effects.
pregnancy
second trimesteravoid if possible
Continue only if clearly needed, consider risks vs benefits
standard prenatal monitoring
Use with caution and monitor for adverse effects.
pregnancy
third trimesteravoid if possible
Consider discontinuing therapy near end of pregnancy due to potential immune suppression in newborn
monitor newborn for infections
Use with caution and monitor for adverse effects.
lactation
breastfeedinguse with caution
It is unknown whether ixekizumab is present in human milk or if it is absorbed systemically by the infant. A decision should be made whether to discontinue breastfeeding or to discontinue the drug
monitor infant for infections
pediatric_age
adolescentsno adjustment for age 12 and older
Approved for pediatric plaque psoriasis in patients 6 years and older. Dosing differs by weight for younger children
regular assessment of growth and development
pediatric_age
childrenweight-based dosing for children under 50kg
For pediatric patients 6 to less than 18 years with moderate to severe plaque psoriasis, dosing is weight-based
monitor for infections and tuberculosis
geriatric
elderlyno specific dose adjustment required
No overall differences in efficacy or safety observed in clinical trials for patients 65 years and older
standard geriatric monitoring including infection surveillance
renal_impairment
mild to moderateno dose adjustment required
Ixekizumab is a monoclonal antibody and is not eliminated by renal pathways
standard renal function monitoring
renal_impairment
severeno dose adjustment required
Limited data available for severe renal impairment but not expected to require dose adjustment
standard monitoring
hepatic_impairment
mild to moderateno dose adjustment required
Ixekizumab is metabolized via proteolysis and not through hepatic pathways
standard hepatic function monitoring
hepatic_impairment
severeuse with caution
Limited clinical data in severe hepatic impairment; use only if benefits outweigh risks
close monitoring of liver function
Use with caution and monitor for adverse effects.
Statistics and clinical data
Drug class
Ixekizumab is a monoclonal antibody that inhibits interleukin-17A
Common uses
FDA-approved therapeutic indications
FDA approval year
Initial FDA approval date for Ixekizumab (Taltz)
Route of administration
Method of drug delivery
Contraindications
Conditions and patient states where this medication should be avoided or used with caution.
Do not use (1)
Known allergy to this medication or its components
Use caution (1)
Consult healthcare provider for benefits vs risks assessment
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy